Feature | March 29, 2012

Trial Data Shows Superior Efficacy of Promus Element Compared to Xience V

The Boston Scientific Promus Element stent.

Abbott's Xience V stent. The stent is also sold by Boston Scientific under an agreement with Abbott as the Promus stent.

March 29, 2012 – Two-year follow-up data from the pivotal PLATINUM Workhorse trial comparing the safety and effectiveness of the Promus Element and Xience V everolimus-eluting coronary stents demonstrated superior efficacy of the Promus. The results were presented at the American College of Cardiology (ACC) Annual Scientific Session by Gregg W. Stone, M.D., professor of medicine and director of research and education at the Center for Interventional Vascular Therapy at Columbia University Medical Center/New York-Presbyterian Hospital. He was the global principal investigator of the trial. 

The outcomes reported at 12 months remained comparable at two years for the two stents.  However, an additional landmark analysis of outcomes from year one to year two demonstrated superior efficacy of the Promus Element during this 12-month period of follow-up.  

“The Promus Element platinum chromium stent continues to demonstrate excellent safety and effectiveness with low rates of cardiac death, myocardial infarction, stent thrombosis and repeat revascularization,” Stone said.  “These long-term results confirm that this device is an effective option for treating patients with coronary artery disease. Of particular note, a statistically significant reduction in recurrent ischemia requiring repeat revascularization procedures was present between the first and second year with the platinum chromium stent.  This finding is potentially important, but must be confirmed by longer-term follow-up.”

The trial reported a two-year target lesion failure (TLF) rate of 4.4 percent for the Promus Element, compared to 5.8 percent for the Xience V (p=0.32).  The Promus Element demonstrated numerically lower but not statistically different event rates than the Xience V in TLF components at two years, including cardiac death related to the target vessel (0.9 vs. 1.1 percent, respectively, p=0.98), myocardial infarction (MI) related to the target vessel (1.2 vs. 2.1 percent, p=0.28) and ischemia-driven target lesion revascularization (TLR, 2.4 vs. 4 percent, p=0.12).  Low rates of target vessel revascularization (TVR, 4.2 percent vs. 5.6 percent, p=0.3) and stent thrombosis (ARC definite/probable, 0.5 percent vs. 0.7 percent, p=0.99) were observed at two years for both stents.

In a landmark analysis of event rates from year one to year two, the Promus Element demonstrated statistically significant differences in TLF (1.2 vs. 3 percent, p=0.04, 56 percent relative reduction), and TLR (0.7 vs. 2.2 percent, p=0.02, 67 percent relative reduction) compared to the Xience V, showing superior efficacy of the Promus Element from 12 months to two years.

Trial results also confirmed a previously reported significant reduction in unplanned (bail-out or emergency) stenting with the Promus Element (5.9  vs. 9.8 percent, p=0.004), including a significantly lower rate of inadequate lesion coverage or “geographic miss” (1.4 vs. 3.4 percent, p=0.01).  Boston Scientific said these clinical observations reflect the results of comparative bench and animal studies, which demonstrated the enhanced visibility and deliverability of the Promus Element stent relative to the Xience V stent.

The prospective, multicenter, randomized PLATINUM Workhorse trial enrolled 1,530 patients with up to two de novo lesions at 132 clinical sites worldwide.  The trial met its primary endpoint of 12-month target lesion failure demonstrating non-inferiority for the platinum chromium Promus  Element compared to the cobalt chromium Xience V.  The comprehensive PLATINUM clinical program is evaluating the safety and effectiveness of the Promus Element in six multi-center studies totaling more than 1,900 patients, including single-arm studies evaluating small vessels, long lesions, pharmacokinetics, and quantitative coronary angiography and intravascular ultrasound data. 

Boston Scientific received CE mark approval for the Promus Element stent in 2009 and for the Promus Element Plus in 2011.  In the United States, the Promus Element Plus stent was approved by the U.S. Food and Drug Administration in 2011. 

For more information: www.bostonscientific.com

Related Content

Dee Dee Wang runs Henry Ford Hospital's 3D printing lab for its complex structural heart cardiology program.

Dee Dee Wang, M.D., runs Henry Ford Hospital's 3-D printing lab that supports its complex structural heart program.

Feature | 3-D Printing| October 13, 2017 | Dave Fornell
Three-dimensional (3-D) printed anatomic models created from a patient’s computed tomography (CT), magnetic resonance...
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
New Evaluation Sends Low-Risk ER Chest Pain Patients Home Sooner
News | Cardiac Diagnostics| October 10, 2017
A new evaluation to determine whether emergency room patients with chest pain can go home and follow up with their...
Videos | Chronic Total Occlusion (CTO)| October 09, 2017
Bill Lombardi, M.D., director of complex coronary artery interventions at the University of Washington, discusses the
BTG Acquires Roxwood Medical
News | Business| October 05, 2017
BTG plc announced it has acquired Roxwood Medical, provider of advanced cardiovascular specialty catheters used in the...
TVA Medical Receives CE Mark for Next-Generation EverlinQ 4 EndoAVF System
News | Vascular Access| October 04, 2017
TVA Medical Inc. announced that its everlinQ 4 endoAVF System has received CE Mark in the European Union. The...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
Reflow Medical's Wingman Crossing Catheter Receives FDA Clearance for Coronary Indication
News | Catheters| October 02, 2017
October 2, 2017 — Reflow Medical Inc. announced that the company has received 510(k) clearance from the U.S.
Medtronic Announces Post-Market Study for CoreValve Evolut Pro System
News | Heart Valve Technology| October 02, 2017
Medtronic plc recently announced a new post-market clinical study to evaluate its CoreValve Evolut Pro valve in...
TherOx Gains FDA PMA Approval for SSO2 Therapy System
Technology | Cath Lab| September 29, 2017
September 29, 2017 — TherOx Inc. announced that the U.S.
Overlay Init